IRLAB Therapeutics AB (publ) - Asset Resilience Ratio

Latest as of December 2025: 59.23%

IRLAB Therapeutics AB (publ) (IRLAB-A) has an Asset Resilience Ratio of 59.23% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Skr81.86 Million

≈ $8.81 Million USD Cash + Short-term Investments

Total Assets

Skr138.21 Million

≈ $14.87 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how IRLAB Therapeutics AB (publ)'s Asset Resilience Ratio has changed over time. Check asset allocation strategy of IRLAB Therapeutics AB (publ) to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down IRLAB Therapeutics AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of IRLAB Therapeutics AB (publ).

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr81.86 Million	59.23%
Short-term Investments	Skr0.00	0%
Total Liquid Assets	Skr81.86 Million	59.23%

Asset Resilience Insights

Very High Liquidity: IRLAB Therapeutics AB (publ) maintains exceptional liquid asset reserves at 59.23% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

IRLAB Therapeutics AB (publ) Industry Peers by Asset Resilience Ratio

Compare IRLAB Therapeutics AB (publ)'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	0.05%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Syndax Pharmaceuticals Inc NASDAQ:SNDX	Biotechnology	46.79%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	63.47%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for IRLAB Therapeutics AB (publ) (2016–2025)

The table below shows the annual Asset Resilience Ratio data for IRLAB Therapeutics AB (publ).

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	59.23%	Skr81.86 Million ≈ $8.81 Million	Skr138.21 Million ≈ $14.87 Million	+10.10pp
2024-12-31	49.13%	Skr66.92 Million ≈ $7.20 Million	Skr136.21 Million ≈ $14.66 Million	-13.72pp
2023-12-31	62.84%	Skr111.31 Million ≈ $11.98 Million	Skr177.12 Million ≈ $19.06 Million	-15.28pp
2022-12-31	78.12%	Skr252.78 Million ≈ $27.20 Million	Skr323.56 Million ≈ $34.82 Million	-6.94pp
2021-12-31	85.07%	Skr401.90 Million ≈ $43.25 Million	Skr472.45 Million ≈ $50.84 Million	+10.21pp
2020-12-31	74.85%	Skr277.01 Million ≈ $29.81 Million	Skr370.07 Million ≈ $39.83 Million	+21.73pp
2019-12-31	53.12%	Skr110.53 Million ≈ $11.89 Million	Skr208.07 Million ≈ $22.39 Million	-6.65pp
2018-12-31	59.77%	Skr134.44 Million ≈ $14.47 Million	Skr224.94 Million ≈ $24.21 Million	+13.93pp
2017-12-31	45.84%	Skr74.71 Million ≈ $8.04 Million	Skr162.97 Million ≈ $17.54 Million	+23.09pp
2016-12-31	22.75%	Skr25.74 Million ≈ $2.77 Million	Skr113.11 Million ≈ $12.17 Million	--

pp = percentage points

About IRLAB Therapeutics AB (publ)

ST:IRLAB-A Sweden Biotechnology

Market Cap

$11.94 Million

Skr110.99 Million SEK

Market Cap Rank

#26583 Global

#574 in Sweden

Share Price

Skr1.31

Change (1 day)

-0.76%

52-Week Range

Skr1.20 - Skr3.36

All Time High

Skr104.95